/content/mofsl-website-adobe/fragments/open-demat-popup
style
hide-in-desktop

TRANSMEDICS GROUP INC Share Price Today: Live Updates & Key Insights

TRANSMEDICS GROUP INC share price today is $122, up -5.94%. The stock opened at $127.25 against the previous close of $128.97, with an intraday high of $127.86 and low of $120.82.

TRANSMEDICS GROUP INC Share Price Chart

style
pb-0

TRANSMEDICS GROUP INC

us-stock
To Invest in {{usstockname}}
/content/mofsl-website-adobe/demat-form-fields
style
sticky-block,pt-0
us-stock
style
pt-0

TRANSMEDICS GROUP INC Share Price Performance

$122 -0.0594(-5.94%) TMDX at 13 Mar 2026 03:32 PM Medical Devices
Lowest Today 120.82
Highest Today 127.86
Today’s Open 127.25
Prev. Close 128.97
52 Week High 156.00
52 Week Low 62.23
Day’s Range: Low 120.82 High 127.86
52-Week Range: Low 62.23 High 156.00
1 day return -
1 Week return -6.15
1 month return -5.17
3 month return -1.31
6 month return +6.42
1 year return +88.65
3 year return +66.39
5 year return +182.96
10 year return -

TRANSMEDICS GROUP INC Institutional Holdings

BlackRock Inc 15.54

FMR Inc 14.80

Vanguard Group Inc 10.51

iShares Core S&P Small-Cap ETF 6.04

State Street Corp 3.73

UBS Asset Mgmt Americas Inc 3.12

Vanguard Total Stock Mkt Idx Inv 2.98

Macquarie Group Ltd 2.64

UBS Group AG 2.50

iShares Russell 2000 ETF 2.38

Geode Capital Management, LLC 2.37

JPMorgan Chase & Co 2.29

Vanguard Small Cap Index 2.14

Driehaus Capital Management LLC 2.08

The Goldman Sachs Group Inc 2.05

Hood River Capital Management LLC 2.01

Fidelity Advisor New Insights I 1.79

Fidelity VIP Contrafund Initial 1.72

Fidelity Small Cap Growth 1.67

Eventide Asset Management, LLC 1.60

Morgan Stanley - Brokerage Accounts 1.60

Marshall Wace Asset Management Ltd 1.58

Dimensional Fund Advisors, Inc. 1.43

Nomura Small Cap Core I 1.41

Eventide Gilead N 1.34

Two Sigma Investments LLC 1.27

Wellington Management Company LLP 1.26

Vanguard Small Cap Growth Index Inv 1.19

T. Rowe Price Associates, Inc. 1.16

Strategic Advisers Fidelity US TtlStk 1.13

Amvescap Plc. 1.12

Fidelity VIP Mid Cap Initial 1.12

Vanguard Institutional Extnd Mkt Idx Tr 1.08

Hood River Small-Cap Growth Instl 1.07

Fidelity OTC 1.06

Fidelity Series Opportunistic Insights 1.00

Fidelity Small Cap Index 0.96

State Street SPDR Port S&P 600 Sm CpETF 0.93

iShares S&P Small-Cap 600 Growth ETF 0.85

Fidelity Small Cap Growth K6 0.84

TRANSMEDICS GROUP INC Market Status

Strong Buy: 5

Buy: 1

Hold: 3

Sell: 0

Strong Sell: 0

TRANSMEDICS GROUP INC Fundamentals

Market Cap 4423.99 M

PB Ratio 9.4874

PE Ratio 26.4283

Enterprise Value 4519.39 M

Total Assets 1068.37 M

Volume 949064

TRANSMEDICS GROUP INC Company Financials

Annual Revenue FY25:605494000 605.5M, FY23:191824000 191.8M, FY22:93459000 93.5M, FY21:30262000 30.3M, FY20:25639000 25.6M

Annual Profit FY25:362806000 362.8M, FY23:126872000 126.9M, FY22:65272000 65.3M, FY21:21159000 21.2M, FY20:16635000 16.6M

Annual Net worth FY25:190291000 190.3M, FY23:-35779000 -35.8M, FY22:-36231000 -36.2M, FY21:-44215000 -44.2M, FY20:-28748000 -28.7M

Quarterly Revenue Q4/2025:160764000 160.8M, Q3/2025:143823000 143.8M, Q2/2025:157370000 157.4M, Q1/2025:143537000 143.5M, Q3/2024:108761000 108.8M

Quarterly Profit Q4/2025:93414000 93.4M, Q3/2025:84575000 84.6M, Q2/2025:96589000 96.6M, Q1/2025:88228000 88.2M, Q3/2024:60845000 60.8M

Quarterly Net worth Q4/2025:105383000 105.4M, Q3/2025:24319000 24.3M, Q2/2025:34907000 34.9M, Q1/2025:25682000 25.7M, Q3/2024:4216000 4.2M

About TRANSMEDICS GROUP INC & investment objective

Company Information TransMedics Group, Inc., a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company provides Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body. Its OCS includes OCS LUNG for the preservation of standard criteria donor lungs for double-lung transplantation; OCS Heart, a technology for preservation of DBD donor hearts deemed unsuitable due to limitations of cold storage and for ex vivo reanimation, functional monitoring, and beating-heart preservation of donation-after-circulatory-death hearts; and OCS Liver for the preservation of DBD and DCD of donor livers. The company also developed national OCS program, a turnkey solution for outsourced organ retrieval; and provides OCS organ management and logistics services, including aviation and ground transportation, and other coordination activity. The company was founded in 1998 and is headquartered in Andover, Massachusetts.

Organisation Medical Devices

Employees 898

Industry Medical Devices

CEO Dr. Waleed H. Hassanein M.D.

Trading and brokerage services provided by

Technology Services provided by Motilal Oswal Financial Services:

Disclaimer: These services are not for exchange traded products. The securities quoted are exemplary and not recommendatory. Please be informed that US Stocks are not exchange traded funds in India and Motilal Oswal Financial Services acts in the capacity of facilitator of this product. All disputes with respect to the transaction facilitation services, would not have access to Indian Exchange investor redressal forum or Arbitration mechanism in India. T&C apply*

Take your next step

Talk to our investment advisor for stock recommendations
Left
Get expert assistance for portfolio management
Right
style
align-center,button-arrow